UNITED THERAPEUTICS (UTHR) Common Equity: 2009-2025
Historic Common Equity for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Sep 2025 value amounting to $6.6 billion.
- UNITED THERAPEUTICS's Common Equity rose 8.02% to $6.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 billion, marking a year-over-year increase of 8.02%. This contributed to the annual value of $6.4 billion for FY2024, which is 7.67% up from last year.
- Per UNITED THERAPEUTICS's latest filing, its Common Equity stood at $6.6 billion for Q3 2025, which was down 8.13% from $7.2 billion recorded in Q2 2025.
- UNITED THERAPEUTICS's 5-year Common Equity high stood at $7.2 billion for Q2 2025, and its period low was $3.4 billion during Q1 2021.
- For the 3-year period, UNITED THERAPEUTICS's Common Equity averaged around $6.0 billion, with its median value being $6.0 billion (2023).
- Data for UNITED THERAPEUTICS's Common Equity shows a peak YoY climbed of 27.52% (in 2025) over the last 5 years.
- Over the past 5 years, UNITED THERAPEUTICS's Common Equity (Quarterly) stood at $4.0 billion in 2021, then increased by 21.16% to $4.8 billion in 2022, then climbed by 24.77% to $6.0 billion in 2023, then grew by 7.67% to $6.4 billion in 2024, then grew by 8.02% to $6.6 billion in 2025.
- Its Common Equity stands at $6.6 billion for Q3 2025, versus $7.2 billion for Q2 2025 and $6.8 billion for Q1 2025.